Business Context and Reporting Period
Company: Whitehawk Therapeutics, Inc. (formerly Aadi Bioscience, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Whitehawk is an oncology therapeutics company transitioning from a commercial-stage business to a preclinical-stage biopharmaceutical company. Historically, the company commercialized FYARRO (nab-sirolimus) for advanced malignant PEComa. In December 2024, the company entered into a definitive agreement to divest the FYARRO business and simultaneously in-licensed a portfolio of three next-generation antibody-drug conjugates (ADCs) from WuXi Biologics. The company changed its name to Whitehawk Therapeutics, Inc. in March 2025.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Net Product Sales | $25,983 | $24,354 |
| Total Operating Expenses | $93,441 | $96,287 |
| Net Loss | $(63,691) | $(65,765) |
| Cash, Cash Equivalents & Short-Term Investments (Dec 31, 2024) | $47,200 | $108,845 |
| Accumulated Deficit (Dec 31, 2024) | $(332,654) | $(268,963) |
Liquidity Update (Subsequent Events): As of March 26, 2025, following the closing of the FYARRO divestiture and a PIPE financing, the company added approximately $202.4 million to its cash position. This includes $102.4 million from the divestiture and $100.0 million from the PIPE financing.
Material Changes vs. Prior Period
- Strategic Pivot: The company divested its sole revenue-generating asset, FYARRO, to KAKEN Investments Inc. for $102.4 million (closed March 25, 2025). Consequently, the company no longer operates the FYARRO business and expects no product revenue for the foreseeable future.
- Pipeline Acquisition: Entered a license agreement with WuXi Biologics for three preclinical ADC therapies (HWK-007, HWK-016, HWK-206) targeting PTK7, MUC16, and SEZ6. Paid a $6.0 million upfront fee in Q4 2024, with an additional $38.0 million due in April 2025.
- Operational Restructuring: Recorded $2.6 million in restructuring charges in 2024 following a 32% workforce reduction after halting the PRECISION1 Phase 2 trial for FYARRO in solid tumors.
- Revenue Growth: FYARRO net sales increased 6.7% year-over-year to $26.0 million, driven by stronger demand prior to the divestiture.
- Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased by $7.8 million to $36.7 million, primarily due to reduced commercial and marketing expenses and personnel costs.
Guidance, Outlook, and Risks
Outlook and Guidance:
- Cash Runway: Management believes existing cash, cash equivalents, and short-term investments (post-transaction) will fund planned operations into 2028.
- Development Timeline: Anticipates submitting Investigational New Drug (IND) applications for the three ADC therapies within the next 12 to 24 months:
- HWK-007 (PTK7): Second half of 2025.
- HWK-016 (MUC16): End of 2025.
- HWK-206 (SEZ6): Mid-2026.
Key Risks and Contingencies:
- Preclinical Stage: The new pipeline is entirely preclinical; there is no guarantee of regulatory approval or commercial success.
- Capital Requirements: The company expects to continue incurring significant net losses and will require additional capital to advance the ADC programs.
- Third-Party Reliance: Relies on WuXi Biologics and Hangzhou DAC (both based in China) for manufacturing and technology. This exposes the company to geopolitical risks, including potential U.S. legislation (e.g., BIOSECURE Act) targeting Chinese biotechnology entities.
- Intellectual Property: Success depends on maintaining in-licensed patent rights and defending against third-party claims.
Investor Verification Checklist
- Divestiture Closing: Confirm the final closing date and net proceeds received from the FYARRO sale to KAKEN (reported as $102.4 million).
- License Agreement Terms: Verify the payment schedule for the remaining $38.0 million upfront fee to WuXi Biologics and the specific milestones triggering the potential $805.0 million in future payments.
- Capital Position: Monitor the company's cash burn rate post-transaction to validate the "into 2028" runway estimate.
- Regulatory Filings: Track the submission dates of the IND applications for HWK-007, HWK-016, and HWK-206 against the stated 2025/2026 timelines.
- Geopolitical Exposure: Assess the impact of U.S.-China trade relations and the potential passage of the BIOSECURE Act on the company's supply chain and manufacturing capabilities.